Published in J Child Adolesc Psychopharmacol on October 01, 2009
Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med (2010) 1.23
Advances in understanding and treating ADHD. BMC Med (2011) 1.21
An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother (2011) 1.15
Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic α₁ - and α₂-receptors. Biol Psychiatry (2011) 1.08
The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother (2010) 0.91
Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. Clin Drug Investig (2016) 0.85
Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D (2013) 0.82
A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol (2013) 0.82
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics (2012) 0.80
Drug therapy of attention deficit hyperactivity disorder: current trends. Mens Sana Monogr (2012) 0.78
Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis (2012) 0.77
Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2014) 0.77
Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry (2016) 0.77
Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D (2013) 0.76
Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol (2016) 0.76
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat (2015) 0.76
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD. BMC Psychiatry (2016) 0.75
A case series on the heightened autonomic response due to guanfacine and amphetamine interaction. J Clin Psychopharmacol (2015) 0.75
ANALYSIS OF DAYTIME SLEEPINIESS IN ADOLESCENTS BY THE PEDIATRIC DAYTIME SLEEPINESS SCALE: A SYSTEMATIC REVIEW. Rev Paul Pediatr (2017) 0.75
Attention-deficit hyperactivity disorder. Lancet (2005) 5.75
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry (2002) 4.57
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry (2001) 3.87
Treatment of ADHD in children with tics: a randomized controlled trial. Neurology (2002) 3.63
Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry (1996) 3.56
Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am (2000) 3.25
Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry (1997) 2.68
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics (2008) 2.22
A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry (2001) 1.95
An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (1995) 1.81
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry (2009) 1.73
Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry (2008) 1.27
alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol (2007) 1.21
Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am J Psychiatry (1995) 1.18
A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry (2003) 1.16
Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol (2004) 1.10
Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep (2006) 1.04
A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) (2000) 1.04
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry (2008) 1.04
Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol (1991) 1.03
A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther (2007) 1.00
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy (2007) 1.00
Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry (1995) 0.92
Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol (2009) 1.05
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord (2014) 1.02
Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. Postgrad Med (2008) 1.01
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia. Child Adolesc Psychiatry Ment Health (2009) 0.89
Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. Curr Med Res Opin (2010) 0.88
Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry (2004) 0.84
Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf (2004) 0.82
GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. J Am Acad Child Adolesc Psychiatry (2002) 0.78
Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Curr Med Res Opin (2015) 0.78
Bipolar II disorder: current and future treatment options. Ann Clin Psychiatry (2006) 0.77
Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2009) 0.76
Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate. J Child Adolesc Psychopharmacol (2013) 0.75
Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol (2012) 0.75